Table 2 CAR-T cell therapy under clinical trials for CRC
Target | Phase | Sponsor | NCT number |
|---|---|---|---|
CEA | eI* | Ruijin Hospital | NCT04513431 |
EGFR | I/II | Shenzhen Second People's Hospital | NCT03152435 |
EGFR/IL12 | I | Shenzhen Second People's Hospital | NCT03542799 |
αPD1/MSLN | eI | Shanghai Cell Therapy Group Co.,Ltd | NCT04503980 |
NKG2D | I | Celyad Oncology SA | NCT03692429 |
MUC1 | I/II | PersonGen BioTherapeutics (Suzhou) Co., Ltd | NCT02617134 |
CEA | I/II | Shanghai GeneChem Co., Ltd | NCT02959151 |
NKG2D | I | Celyad Oncology SA | NCT03370198 |
NKG2D | I | Celyad Oncology SA | NCT03310008 |
NKG2DL | I | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | NCT04550663 |
CEA | I/II | Chongqing Precision Biotech Co., Ltd | NCT04348643 |
CEA | I | Southwest Hospital, China | NCT02349724 |
HER-2 | I/II | Zhi Yang | NCT02713984 |
CEA | I | Sorrento Therapeutics, Inc | NCT03682744 |
C-met | I/II | Shenzhen BinDeBio Ltd | NCT03638206 |
HER-2 | I | Baylor College of Medicine | NCT03740256 |
NKG2DL | I | CytoMed Therapeutics Pte Ltd | NCT04107142 |
CD133 | I/II | Chinese PLA General Hospital | NCT02541370 |